✦ LIBER ✦

Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study

✍ Scribed by Bergmann, Lothar; Goebell, Peter J.; Kube, Ulrich; Kindler, Manfred; Herrmann, Edwin; Janssen, Jan; Schmitz, Joerg; Weikert, Steffen; Steiner, Gabriel; Jakob, Andreas; Staehler, Michael D.; Steiner, Thomas; Overkamp, Friedrich; Albrecht, Michael; Guderian, Gernot; Doehn, Christian

Book ID: 120546587
Publisher: S. Karger AG
Year: 2013
Tongue: English
Weight: 431 KB
Volume: 36
Category: Article
ISSN: 0378-584X
DOI: 10.1159/000348522

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An international expanded-access program

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

✍ Viktor Grünwald; Pierre I. Karakiewicz; Sevil E. Bavbek; Kurt Miller; Jean-Pasca 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 257 KB

7108 Phase II study of IMC-1121B in pati

7108 Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12–0605/NCT00515697)

✍ Garcia, J.A.; Hudes, G.; Choueiri, T.K.; Stadler, W.M.; Wood, L.; Bhatia, S.; Yo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

83 International, expanded-access progra

83 International, expanded-access programme of everolimus in patients with metastatic renal cell carcinoma who progressed after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: Sub-analysis of European patients

✍ S. Bracarda; S. Rottey; A. Bahl; C. Eichelberg; B. Mellado; L. Mangel; J. Mardia 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 35 KB

Comparative efficacy of vascular endothe

Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI

✍ Kwonoh Park, Jae-Lyun Lee, Inkeun Park, Seongjoon Park, Yongcheol Ahn, Jin-Hee A 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 193 KB

Safety and efficacy of everolimus in Chi

Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

✍ Jun Guo, Yiran Huang, Xu Zhang, Fangjian Zhou, Yinghao Sun, Shukui Qin… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 194 KB

Everolimus in metastatic renal cell carc

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

✍ E. Calvo; B. Escudier; R.J. Motzer; S. Oudard; T.E. Hutson; C. Porta; S. Bracard 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 262 KB